S&P 500   5,088.80
DOW   39,131.53
QQQ   437.56
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Analysts boosted Snowflake stock, big firms are buying now
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
3 Chinese stocks poised for rebound
S&P 500   5,088.80
DOW   39,131.53
QQQ   437.56
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Analysts boosted Snowflake stock, big firms are buying now
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
3 Chinese stocks poised for rebound
S&P 500   5,088.80
DOW   39,131.53
QQQ   437.56
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Analysts boosted Snowflake stock, big firms are buying now
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
3 Chinese stocks poised for rebound
S&P 500   5,088.80
DOW   39,131.53
QQQ   437.56
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Analysts boosted Snowflake stock, big firms are buying now
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
3 Chinese stocks poised for rebound

Surgical Science Sweden AB (publ) (SUSRF) Stock Forecast & Price Target

$11.84
-1.96 (-14.20%)
(As of 10/11/2023)

Surgical Science Sweden AB (publ) Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 1 Analyst Ratings

Analysts' Consensus Price Target

N/A

TypeCurrent Forecast
2/26/23 to 2/26/24
1 Month Ago
1/27/23 to 1/27/24
3 Months Ago
11/28/22 to 11/28/23
1 Year Ago
2/26/22 to 2/26/23
Consensus Rating
Buy
Buy
Buy
N/A
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
N/A
Consensus Price TargetN/AN/AN/AN/A
Predicted UpsideN/AN/AN/AN/A
Get Surgical Science Sweden AB (publ) Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for SUSRF and its competitors with MarketBeat's FREE daily newsletter.


SUSRF Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SUSRF Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Surgical Science Sweden AB (publ) Stock vs. The Competition

TypeSurgical Science Sweden AB (publ)Medical CompaniesS&P 500
Consensus Rating Score
3.00
2.67
2.48
Consensus RatingBuyModerate BuyHold
Predicted Upside1,182.53% Upside7.96% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/23/2023DNB Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 09:29 AM ET.












SUSRF Price Target - Frequently Asked Questions

What is Surgical Science Sweden AB (publ)'s consensus rating?

According to the issued ratings of 1 analysts in the last year, the consensus rating for Surgical Science Sweden AB (publ) stock is Buy based on the current 1 buy rating for SUSRFthe . Learn more on SUSRF's analyst rating history.

Do Wall Street analysts like Surgical Science Sweden AB (publ) more than its competitors?

Analysts like Surgical Science Sweden AB (publ) more than other Medical companies. The consensus rating for Surgical Science Sweden AB (publ) is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how SUSRF compares to other companies.


Stock Ratings Reports and Tools

This page (OTCMKTS:SUSRF) was last updated on 2/26/2024 by MarketBeat.com Staff